Search

Your search keyword '"Jóźwiak, Katarzyna"' showing total 375 results
Start Over Author "Jóźwiak, Katarzyna"
375 results on '"Jóźwiak, Katarzyna"'

1. Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status

Author

Wang, Yuwei, Dackus, Gwen M. H. E., Rosenberg, Efraim H., Cornelissen, Sten, de Boo, Leonora W., Broeks, Annegien, Brugman, Wim, Chan, Terry W. S., van Diest, Paul J., Hauptmann, Michael, ter Hoeve, Natalie D., Isaeva, Olga I., de Jong, Vincent M. T., Jóźwiak, Katarzyna, Kluin, Roelof J. C., Kok, Marleen, Koop, Esther, Nederlof, Petra M., Opdam, Mark, Schouten, Philip C., Siesling, Sabine, van Steenis, Charlaine, Voogd, Adri C., Vreuls, Willem, Salgado, Roberto F., Linn, Sabine C., and Schmidt, Marjanka K.

Published
2024
Full Text
View/download PDF

5. External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer

Author

Wang, Yuwei, Broeks, Annegien, Giardiello, Daniele, Hauptmann, Michael, Jóźwiak, Katarzyna, Koop, Esther A., Opdam, Mark, Siesling, Sabine, Sonke, Gabe S., Stathonikos, Nikolas, ter Hoeve, Natalie D., van der Wall, Elsken, van Deurzen, Carolien H.M., van Diest, Paul J., Voogd, Adri C., Vreuls, Willem, Linn, Sabine C., Dackus, Gwen M.H.E., and Schmidt, Marjanka K.

Published
2023
Full Text
View/download PDF

8. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Author

Reijers, Irene L. M., Menzies, Alexander M., van Akkooi, Alexander C. J., Versluis, Judith M., van den Heuvel, Noëlle M. J., Saw, Robyn P. M., Pennington, Thomas E., Kapiteijn, Ellen, van der Veldt, Astrid A. M., Suijkerbuijk, Karijn P. M., Hospers, Geke A. P., Rozeman, Elisa A., Klop, Willem M. C., van Houdt, Winan J., Sikorska, Karolina, van der Hage, Jos A., Grünhagen, Dirk J., Wouters, Michel W., Witkamp, Arjen J., Zuur, Charlotte L., Lijnsvelt, Judith M., Torres Acosta, Alejandro, Grijpink-Ongering, Lindsay G., Gonzalez, Maria, Jóźwiak, Katarzyna, Bierman, Carolien, Shannon, Kerwin F., Ch’ng, Sydney, Colebatch, Andrew J., Spillane, Andrew J., Haanen, John B. A. G., Rawson, Robert V., van de Wiel, Bart A., van de Poll-Franse, Lonneke V., Scolyer, Richard A., Boekhout, Annelies H., Long, Georgina V., and Blank, Christian U.

Published
2022
Full Text
View/download PDF

12. Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status

Author

Pathologie, Cancer, Pathologie Pathologen staf, Wang, Yuwei, Dackus, Gwen M H E, Rosenberg, Efraim H, Cornelissen, Sten, de Boo, Leonora W, Broeks, Annegien, Brugman, Wim, Chan, Terry W S, van Diest, Paul J, Hauptmann, Michael, Ter Hoeve, Natalie D, Isaeva, Olga I, de Jong, Vincent M T, Jóźwiak, Katarzyna, Kluin, Roelof J C, Kok, Marleen, Koop, Esther, Nederlof, Petra M, Opdam, Mark, Schouten, Philip C, Siesling, Sabine, van Steenis, Charlaine, Voogd, Adri C, Vreuls, Willem, Salgado, Roberto F, Linn, Sabine C, Schmidt, Marjanka K, Pathologie, Cancer, Pathologie Pathologen staf, Wang, Yuwei, Dackus, Gwen M H E, Rosenberg, Efraim H, Cornelissen, Sten, de Boo, Leonora W, Broeks, Annegien, Brugman, Wim, Chan, Terry W S, van Diest, Paul J, Hauptmann, Michael, Ter Hoeve, Natalie D, Isaeva, Olga I, de Jong, Vincent M T, Jóźwiak, Katarzyna, Kluin, Roelof J C, Kok, Marleen, Koop, Esther, Nederlof, Petra M, Opdam, Mark, Schouten, Philip C, Siesling, Sabine, van Steenis, Charlaine, Voogd, Adri C, Vreuls, Willem, Salgado, Roberto F, Linn, Sabine C, and Schmidt, Marjanka K

Published
2024

13. The cumulative burden of self-reported, clinically relevant outcomes in long-term childhood cancer survivors and implications for survivorship care: A DCCSS LATER study

Author

Klinische Fysica RT, Speerpunt, Zorg en O&O, Cancer, Child Health, SCT patientenzorg, Haematologie patientenzorg, Endocrinologie patientenzorg, Brain, PMC Medisch specialisten, Streefkerk, Nina, Teepen, Jop C., Feijen, Elizabeth A.M., Jóźwiak, Katarzyna, van der Pal, Helena J.H., Ronckers, Cecile M., De Vries, Andrica C.H., Van der Heiden-van Der Loo, Margriet, Hollema, Nynke, van den Berg, Marleen, Loonen, Jacqueline, Grootenhuis, Martha A., Bresters, Dorine, Versluys, A. Brigitta, van Dulmen-den Broeder, Eline, van den Heuvel-Eibrink, Marry M., van Leeuwen, Flora E., Neggers, Sebastian J.C.M.M., Van Santen, Hanneke M., Hawkins, Mike, Hauptmann, Michael, Yoneoka, Daisuke, Korevaar, Joke C., Tissing, Wim J.E., Kremer, Leontien C.M., Klinische Fysica RT, Speerpunt, Zorg en O&O, Cancer, Child Health, SCT patientenzorg, Haematologie patientenzorg, Endocrinologie patientenzorg, Brain, PMC Medisch specialisten, Streefkerk, Nina, Teepen, Jop C., Feijen, Elizabeth A.M., Jóźwiak, Katarzyna, van der Pal, Helena J.H., Ronckers, Cecile M., De Vries, Andrica C.H., Van der Heiden-van Der Loo, Margriet, Hollema, Nynke, van den Berg, Marleen, Loonen, Jacqueline, Grootenhuis, Martha A., Bresters, Dorine, Versluys, A. Brigitta, van Dulmen-den Broeder, Eline, van den Heuvel-Eibrink, Marry M., van Leeuwen, Flora E., Neggers, Sebastian J.C.M.M., Van Santen, Hanneke M., Hawkins, Mike, Hauptmann, Michael, Yoneoka, Daisuke, Korevaar, Joke C., Tissing, Wim J.E., and Kremer, Leontien C.M.

Published
2024

15. The role of genetic variants in the prediction of hearing loss due to cisplatin chemoradiotherapy.

Author

Duinkerken, Charlotte W., Chiodo, Sabrina, Hueniken, Katrina, Hauptmann, Michael, Jóźwiak, Katarzyna, Cheng, Dangxiao, Hope, Andrew, Liu, Geoffrey, and Zuur, Charlotte L.

Subjects
GENETIC variation, SENSORINEURAL hearing loss, HEARING levels, SQUAMOUS cell carcinoma, HEARING disorders
Abstract

Background: Concomitant high‐dose cisplatin with radiotherapy is commonly used for treating head and neck squamous cell carcinoma (HNSCC). Cisplatin, often used with radiotherapy, is known for causing irreversible sensorineural hearing loss, with individual variability suggesting a genetic component. This study aims to enhance the predictive ability of the clinical prediction model for cisplatin‐induced hearing loss (CIHL) in HNSCC patients, as outlined in Theunissen et al., by incorporating significant genetic variants. Methods: Conducted at the Netherlands Cancer Institute, this retrospective study included 74 patients treated between 1997 and 2011. Thirty‐one SNPs that were previously associated with CIHL or other cisplatin‐induced toxicities were identified and incorporated into the model. The primary outcome measured was the change in decibels at posttreatment 1‐2‐4 kHz hearing levels per additional minor allele of these SNPs, evaluated using linear mixed‐effects regression models. The model's predictive accuracy was determined by the area under the curve (AUC) using 10‐fold cross‐validation. Results: The rs2289669 SNP in the SLC47A1/MATE1 gene was linked to a significant 2.67 dB increase in hearing loss per allele (95% CI 0.49–4.86, p = 0.017). Incorporating rs2289669 improved the model's AUC from 0.78 to 0.83, a borderline significant improvement (p = 0.073). Conclusions: This study underscores the importance of the rs2289669 SNP in CIHL and demonstrates the potential of combining genetic and clinical data for enhanced predictive models in personalized treatment strategies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. The cumulative burden of self‐reported, clinically relevant outcomes in long‐term childhood cancer survivors and implications for survivorship care: A DCCSS LATER study.

Author

Streefkerk, Nina, Teepen, Jop C., Feijen, Elizabeth A. M., Jóźwiak, Katarzyna, van der Pal, Helena J. H., Ronckers, Cecile M., De Vries, Andrica C. H., Van der Heiden‐van Der Loo, Margriet, Hollema, Nynke, van den Berg, Marleen, Loonen, Jacqueline, Grootenhuis, Martha A., Bresters, Dorine, Versluys, A. Brigitta, van Dulmen‐den Broeder, Eline, van den Heuvel‐Eibrink, Marry M., van Leeuwen, Flora E., Neggers, Sebastian J. C. M. M., Van Santen, Hanneke M., and Hawkins, Mike

Subjects
CHILDHOOD cancer, CANCER survivors, MISSING data (Statistics), TUMOR treatment, CONFIDENCE intervals
Abstract

Background: The aim of this study is to evaluate how cumulative burden of clinically relevant, self‐reported outcomes in childhood cancer survivors (CCSs) compares to a sibling control group and to explore how the burden corresponds to levels of care proposed by existing risk stratifications. Methods: The authors invited 5925 5‐year survivors from the Dutch Childhood Cancer Survivor Study (DCCSS LATER) cohort and their 1066 siblings to complete a questionnaire on health outcomes. Health outcomes were validated by self‐reported medication use or medical record review. Missing data on clinically relevant outcomes in CCSs for whom no questionnaire data were available were imputed with predictive mean matching. We calculated the mean cumulative count (MCC) for clinically relevant outcomes. Furthermore, we calculated 30‐year MCC for groups of CCSs based on primary cancer diagnosis and treatment, ranked 30‐year MCC, and compared the ranking to levels of care according to existing risk stratifications. Results: At median 18.5 years after 5‐year survival, 46% of CCSs had at least one clinically relevant outcome. CCSs experienced 2.8 times more health conditions than siblings (30‐year MCC = 0.79; 95% confidence interval [CI], 0.74–0.85 vs. 30‐year MCC = 0.29; 95% CI, 0.25–0.34). CCSs' burden of clinically relevant outcomes consisted mainly of endocrine and vascular conditions and varied by primary cancer type. The ranking of the 30‐year MCC often did not correspond with levels of care in existing risk stratifications. Conclusions: CCSs experience a high cumulative burden of clinically relevant outcomes that was not completely reflected by current risk stratifications. Choices for survivorship care should extend beyond primary tumor and treatment parameters, and should consider also including CCSs' current morbidity. Survivors of childhood cancer experience a high cumulative burden of clinically relevant outcomes. Choices for survivorship care should extend beyond primary tumor and treatment parameters and should also consider including the current morbidity of childhood cancer survivors. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Cumulative Absolute Risk of Subsequent Colorectal Cancer After Abdominopelvic Radiotherapy Among Childhood Cancer Survivors: A PanCareSurFup Study.

Author

Heymer, Emma J., Jóźwiak, Katarzyna, Kremer, Leontien C., Winter, David L., de Vathaire, Florent, Sunguc, Ceren, Sugden, Elaine, Kok, Judith L., van der Pal, Helena J.H., Hjorth, Lars, Jakab, Zsuzsanna, Maule, Milena M., Haupt, Riccardo, Bagnasco, Francesca, Terenziani, Monica, Diallo, Ibrahima, Gunnes, Maria W., Sommer, Grit, Zadravec Zaletel, Lorna, and Kuehni, Claudia E.

Published
2024
Full Text
View/download PDF

33. Fermentation Quality and Chemical Composition of Industrial Hemp (Cannabis sativa L.) Silage Inoculated with Bacterial Starter Cultures—A Pilot Study

Author

Wróbel, Barbara, primary, Hryniewicz, Marek, additional, Kulkova, Iryna, additional, Mazur, Kamila, additional, Jakubowska, Zuzanna, additional, Borek, Kinga, additional, Dobrzyński, Jakub, additional, Konieczna, Anita, additional, Miecznikowski, Antoni, additional, Piasecka-Jóźwiak, Katarzyna, additional, and Fabiszewska, Agata, additional

Published
2023
Full Text
View/download PDF

34. Supplementary Figure from De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial

Author

Gluz, Oleg, primary, Nitz, Ulrike, primary, Kolberg-Liedtke, Cornelia, primary, Prat, Aleix, primary, Christgen, Matthias, primary, Kuemmel, Sherko, primary, Mohammadian, Mohammad Parsa, primary, Gebauer, Daniel, primary, Kates, Ronald, primary, Paré, Laia, primary, Grischke, Eva-Maria, primary, Forstbauer, Helmut, primary, Braun, Michael, primary, Warm, Mathias, primary, Hackmann, John, primary, Uleer, Christoph, primary, Aktas, Bahriye, primary, Schumacher, Claudia, primary, Wuerstlein, Rachel, primary, Graeser, Monika, primary, Pelz, Enrico, primary, Jóźwiak, Katarzyna, primary, zu Eulenburg, Christine, primary, Kreipe, Hans Heinrich, primary, and Harbeck, Nadia, primary

Published
2023
Full Text
View/download PDF

35. Figure S2 from EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy

Author

Puppe, Julian, primary, Opdam, Mark, primary, Schouten, Philip C., primary, Jóźwiak, Katarzyna, primary, Lips, Esther, primary, Severson, Tesa, primary, van de Ven, Marieke, primary, Brambillasca, Chiara, primary, Bouwman, Peter, primary, van Tellingen, Olaf, primary, Bernards, René, primary, Wesseling, Jelle, primary, Eichler, Christian, primary, Thangarajah, Fabinshy, primary, Malter, Wolfram, primary, Pandey, Gaurav Kumar, primary, Ozretić, Luka, primary, Caldas, Carlos, primary, van Lohuizen, Maarten, primary, Hauptmann, Michael, primary, Rhiem, Kerstin, primary, Hahnen, Eric, primary, Reinhardt, H. Christian, primary, Büttner, Reinhard, primary, Mallmann, Peter, primary, Schömig-Markiefka, Birgid, primary, Schmutzler, Rita, primary, Linn, Sabine, primary, and Jonkers, Jos, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Legend from EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy

Author

Puppe, Julian, primary, Opdam, Mark, primary, Schouten, Philip C., primary, Jóźwiak, Katarzyna, primary, Lips, Esther, primary, Severson, Tesa, primary, van de Ven, Marieke, primary, Brambillasca, Chiara, primary, Bouwman, Peter, primary, van Tellingen, Olaf, primary, Bernards, René, primary, Wesseling, Jelle, primary, Eichler, Christian, primary, Thangarajah, Fabinshy, primary, Malter, Wolfram, primary, Pandey, Gaurav Kumar, primary, Ozretić, Luka, primary, Caldas, Carlos, primary, van Lohuizen, Maarten, primary, Hauptmann, Michael, primary, Rhiem, Kerstin, primary, Hahnen, Eric, primary, Reinhardt, H. Christian, primary, Büttner, Reinhard, primary, Mallmann, Peter, primary, Schömig-Markiefka, Birgid, primary, Schmutzler, Rita, primary, Linn, Sabine, primary, and Jonkers, Jos, primary

Published
2023
Full Text
View/download PDF

37. External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer

Author

Pathologie Pathologen staf, Pathologie Support, Speerpunt Cancer, Cancer, Pathologie, MS MOD, Pathologie Research, Pathologie Opleiding, Wang, Yuwei, Broeks, Annegien, Giardiello, Daniele, Hauptmann, Michael, Jóźwiak, Katarzyna, Koop, Esther A., Opdam, Mark, Siesling, Sabine, Sonke, Gabe S., Stathonikos, Nikolas, ter Hoeve, Natalie D., van der Wall, Elsken, van Deurzen, Carolien H.M., van Diest, Paul J., Voogd, Adri C., Vreuls, Willem, Linn, Sabine C., Dackus, Gwen M.H.E., Schmidt, Marjanka K., Pathologie Pathologen staf, Pathologie Support, Speerpunt Cancer, Cancer, Pathologie, MS MOD, Pathologie Research, Pathologie Opleiding, Wang, Yuwei, Broeks, Annegien, Giardiello, Daniele, Hauptmann, Michael, Jóźwiak, Katarzyna, Koop, Esther A., Opdam, Mark, Siesling, Sabine, Sonke, Gabe S., Stathonikos, Nikolas, ter Hoeve, Natalie D., van der Wall, Elsken, van Deurzen, Carolien H.M., van Diest, Paul J., Voogd, Adri C., Vreuls, Willem, Linn, Sabine C., Dackus, Gwen M.H.E., and Schmidt, Marjanka K.

Published
2023

38. Development and Validation of Risk Prediction Models for Coronary Heart Disease and Heart Failure After Treatment for Hodgkin Lymphoma

Author

MS Hematologie, Regenerative Medicine and Stem Cells, Cancer, de Vries, Simone, Haaksma, Miriam L, Jóźwiak, Katarzyna, Schaapveld, Michael, Hodgson, David C, Lugtenburg, Pieternella J, Krol, Augustinus D G, Petersen, Eefke J, van Spronsen, Dick Johan, Ahmed, Sameera, Hauptmann, Michael, Aleman, Berthe M P, van Leeuwen, Flora E, MS Hematologie, Regenerative Medicine and Stem Cells, Cancer, de Vries, Simone, Haaksma, Miriam L, Jóźwiak, Katarzyna, Schaapveld, Michael, Hodgson, David C, Lugtenburg, Pieternella J, Krol, Augustinus D G, Petersen, Eefke J, van Spronsen, Dick Johan, Ahmed, Sameera, Hauptmann, Michael, Aleman, Berthe M P, and van Leeuwen, Flora E

Published
2023

39. Development and Validation of Risk Prediction Models for Coronary Heart Disease and Heart Failure After Treatment for Hodgkin Lymphoma

Author

de Vries, Simone, primary, Haaksma, Miriam L., additional, Jóźwiak, Katarzyna, additional, Schaapveld, Michael, additional, Hodgson, David C., additional, Lugtenburg, Pieternella J., additional, Krol, Augustinus D.G., additional, Petersen, Eefke J., additional, van Spronsen, Dick Johan, additional, Ahmed, Sameera, additional, Hauptmann, Michael, additional, Aleman, Berthe M.P., additional, and van Leeuwen, Flora E., additional

Published
2023
Full Text
View/download PDF

47. How Does the Corrected Exhalyzer Software Change the Predictive Value of LCI in Pulmonary Exacerbations in Children with Cystic Fibrosis?

Author

Wojsyk-Banaszak, Irena, Stachowiak, Zuzanna, Więckowska, Barbara, Andrzejewska, Marta, Tąpolska-Jóźwiak, Katarzyna, Szczepankiewicz, Aleksandra, Sobkowiak, Paulina, and Bręborowicz, Anna

Subjects
CYSTIC fibrosis, MEDIAN (Mathematics), GENERALIZED estimating equations, DISEASE exacerbation, CHILD patients
Abstract

Aim: Recently, the most commonly used for multiple breath washout device, the Exhalyzer D, has been shown to overestimate lung clearance index (LCI) results due to a software error. Our study aimed to compare the predictive values of LCI in the CF pulmonary exacerbations (PE) calculated with the updated (3.3.1) and the previous (3.2.1) version of the Spiroware software. Materials and Methods: The measurements were performed during 259 visits in CF pediatric patients. We used 39ΔPE pairs (PE preceded by stable visit) and 138ΔS pairs (stable visit preceded by stable visit) to compare the LCI changes during PE. The areas under the receiver operating curves (AUCROC) and odds ratios were calculated based on the differences between ΔPEs and ΔSs. The exacerbation risk was estimated using a logistic regression model with generalized estimating equations (GEE). Results: There were statistically significant differences in LCI 2.5% median values measured using the two versions of the software in the stable condition but not during PE. The AUCROC for changes between the two consecutive visits for LCI did not change significantly using the updated Spiroware software. Conclusions: Despite the lower median values, using the recalculated LCI values does not influence the diagnostic accuracy of this parameter in CF PE. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy

Author

de Jong, Vincent M.T., primary, Wang, Yuwei, additional, ter Hoeve, Natalie D., additional, Opdam, Mark, additional, Stathonikos, Nikolas, additional, Jóźwiak, Katarzyna, additional, Hauptmann, Michael, additional, Cornelissen, Sten, additional, Vreuls, Willem, additional, Rosenberg, Efraim H., additional, Koop, Esther A., additional, Varga, Zsuzsanna, additional, van Deurzen, Carolien H.M., additional, Mooyaart, Antien L., additional, Córdoba, Alicia, additional, Groen, Emma J., additional, Bart, Joost, additional, Willems, Stefan M., additional, Zolota, Vasiliki, additional, Wesseling, Jelle, additional, Sapino, Anna, additional, Chmielik, Ewa, additional, Ryska, Ales, additional, Broeks, Annegien, additional, Voogd, Adri C., additional, Loi, Sherene, additional, Michiels, Stefan, additional, Sonke, Gabe S., additional, van der Wall, Elsken, additional, Siesling, Sabine, additional, van Diest, Paul J., additional, Schmidt, Marjanka K., additional, Kok, Marleen, additional, Dackus, Gwen M.H.E., additional, Salgado, Roberto, additional, and Linn, Sabine C., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results